Market revenue in 2023 | USD 575.0 million |
Market revenue in 2030 | USD 957.6 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.14% in 2023. Horizon Databook has segmented the Japan blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Japan blood cancer diagnostics market is expected to witness rapid expansion, propelled by the government's substantial investments aimed at combating the country's escalating cancer burden. This surge in cancer prevalence is due to Japan's rapidly aging demographics, with one of the highest median ages worldwide at 44 years.
For instance, in January 2021, Illumina partnered with Otsuka Pharmaceuticals to develop and commercialize an IVD genomic profiling testing kit for patients in Japan with blood cancers. Such partnerships are anticipated to drive market growth in the region.
In another development, in May 2022, Hitachi High-Tech formed a strategic partnership with Invivoscribe, a leading provider of blood cancer testing kits and services, by investing in the company through a minority shareholding.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Japan blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account